Labetuzumab

Identification

Name
Labetuzumab
Accession Number
DB05097
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

Protein structure
Db05097
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • (131I)-MN-14
  • hMN-14
  • MAb hMN14
  • monoclonal antibody hMN-14
International/Other Brands
CEA-Cide
Categories
UNII
EFE6X5M3UY
CAS number
219649-07-7

Pharmacology

Indication

Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"

Pharmacodynamics
Not Available
Mechanism of action

labetuzumab could significantly increase the chemosensitivity of human colon and breast cancer cells in vitro to several anticancer drugs.

TargetActionsOrganism
UCarcinoembryonic antigenNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Labetuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Labetuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Labetuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Labetuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when Labetuzumab is combined with AMG 108.
Food Interactions
Not Available

References

General References
  1. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM: Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005 Sep 20;23(27):6763-70. [PubMed:16170184]
  2. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM: Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007 Sep;14(9):2577-90. Epub 2007 Jun 15. [PubMed:17570017]
External Links
PubChem Substance
347909944
Wikipedia
Labetuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentNeoplasms, Colorectal1
1, 2CompletedTreatmentCancer, Breast / Carcinoma, Colorectal / Colorectal Cancers / Malignant Neoplasm of Colon / Neoplasms, Breast / Neoplasms, Colorectal / Rectal Carcinoma1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Malignant Neoplasm of Colon / Neoplasms, Colorectal / Rectal Carcinoma1
1, 2CompletedTreatmentNeoplasms, Pancreatic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q14081
Uniprot Name
Carcinoembryonic antigen
Molecular Weight
4903.595 Da

Drug created on October 21, 2007 16:23 / Updated on November 02, 2018 06:08